RÉSUMÉ
Helicobacter pylori infection causes chronic gastritis, ulcers, and gastric cancer, making it a threat to human health. Despite the use of antibiotic therapy, the global prevalence of H. pylori infection remains high, necessitating early eradication measures. Immunotherapy, especially vaccine development, is a promising solution in this direction, albeit the selection of an appropriate animal model is critical in efficient vaccine production. Accordingly, we conducted a literature, search and summarized the commonly used H. pylori strains, H. pylori infection-related animal models, and models for evaluating H. pylori vaccines. Based on factors such as the ability to replicate human diseases, strain compatibility, vaccine types, and eliciting of immune responses, we systematically compared the advantages and disadvantages of different animal models, to obtain the informed recommendations. In addition, we have proposed novel perspectives on H. pylori-related animal models to advance research and vaccine evaluation for the prevention and treatment of diseases such as gastric cancer.
Sujet(s)
Vaccins antibactériens , Modèles animaux de maladie humaine , Infections à Helicobacter , Helicobacter pylori , Infections à Helicobacter/prévention et contrôle , Infections à Helicobacter/microbiologie , Infections à Helicobacter/immunologie , Animaux , Vaccins antibactériens/immunologie , Helicobacter pylori/immunologie , HumainsRÉSUMÉ
Helicobacter pylori (H. pylori) is responsible for various chronic or acute diseases, such as stomach ulcers, dyspepsia, peptic ulcers, gastroesophageal reflux, gastritis, lymphoma, and stomach cancers. Although specific drugs are available to treat the bacterium's harmful effects, there is an urgent need to develop a preventive or therapeutic vaccine. Therefore, the current study aims to create a multi-epitope vaccine against H. pylori using lipid nanoparticles. Five epitopes from five target proteins of H. pylori, namely, Urease, CagA, HopE, SabA, and BabA, were used. Immunogenicity, MHC (Major Histocompatibility Complex) bonding, allergenicity, toxicity, physicochemical analysis, and global population coverage of the entire epitopes and final construct were carefully examined. The study involved using various bioinformatic web tools to accomplish the following tasks: modeling the three-dimensional structure of a set of epitopes and the final construct and docking them with Toll-Like Receptor 4 (TLR4). In the experimental phase, the final multi-epitope construct was synthesized using the solid phase method, and it was then enclosed in lipid nanoparticles. After synthesizing the construct, its loading, average size distribution, and nanoliposome shape were checked using Nanodrop at 280 nm, dynamic light scattering (DLS), and atomic force microscope (AFM). The designed vaccine has been confirmed to be non-toxic and anti-allergic. It can bind with different MHC alleles at a rate of 99.05%. The construct loading was determined to be about 91%, with an average size of 54 nm. Spherical shapes were also observed in the AFM images. Further laboratory tests are necessary to confirm the safety and immunogenicity of the multi-epitope vaccine.
Sujet(s)
Vaccins antibactériens , Biologie informatique , Helicobacter pylori , Nanoparticules , Helicobacter pylori/immunologie , Nanoparticules/composition chimique , Vaccins antibactériens/immunologie , Vaccins antibactériens/composition chimique , Biologie informatique/méthodes , Humains , Protéines bactériennes/immunologie , Protéines bactériennes/composition chimique , Épitopes/immunologie , Épitopes/composition chimique , Simulation de docking moléculaire , Antigènes bactériens/immunologie , Antigènes bactériens/composition chimique , Infections à Helicobacter/prévention et contrôle , Infections à Helicobacter/immunologie , Récepteur de type Toll-4/immunologie , Urease/immunologie , Urease/composition chimique , , LiposomesRÉSUMÉ
Acinetobacter baumannii is a gram-negative bacillus prevalent in nature, capable of thriving under various environmental conditions. As an opportunistic pathogen, it frequently causes nosocomial infections such as urinary tract infections, bacteremia, and pneumonia, contributing to increased morbidity and mortality in clinical settings. Consequently, developing novel vaccines against Acinetobacter baumannii is of utmost importance. In our study, we identified 10 highly conserved antigenic proteins from the NCBI and UniProt databases for epitope mapping. We subsequently screened and selected 8 CTL, HTL, and LBL epitopes, integrating them into three distinct vaccines constructed with adjuvants. Following comprehensive evaluations of immunological and physicochemical parameters, we conducted molecular docking and molecular dynamics simulations to assess the efficacy and stability of these vaccines. Our findings indicate that all three multi-epitope mRNA vaccines designed against Acinetobacter baumannii are promising; however, further animal studies are required to confirm their reliability and effectiveness.
Sujet(s)
Acinetobacter baumannii , Vaccins antibactériens , Biologie informatique , Acinetobacter baumannii/immunologie , Acinetobacter baumannii/génétique , Vaccins antibactériens/immunologie , Vaccins antibactériens/génétique , Biologie informatique/méthodes , Épitopes/immunologie , Épitopes/composition chimique , Simulation de docking moléculaire , Infections à Acinetobacter/prévention et contrôle , Infections à Acinetobacter/immunologie , Cartographie épitopique , Vaccins à ARNm , Simulation de dynamique moléculaire , Humains , ARN messager/génétique , ARN messager/immunologie , Antigènes bactériens/immunologie , Antigènes bactériens/génétique , Protéines bactériennes/immunologie , Protéines bactériennes/génétique , Protéines bactériennes/composition chimiqueRÉSUMÉ
Pseudomonas aeruginosa is a complex nosocomial infectious agent responsible for numerous illnesses, with its growing resistance variations complicating treatment development. Studies have emphasized the importance of virulence factors OprE and OprF in pathogenesis, highlighting their potential as vaccine candidates. In this study, B-cell, MHC-I, and MHC-II epitopes were identified, and molecular linkers were active to join these epitopes with an appropriate adjuvant to construct a vaccine. Computational tools were employed to forecast the tertiary framework, characteristics, and also to confirm the vaccine's composition. The potency was weighed through population coverage analysis and immune simulation. This project aims to create a multi-epitope vaccine to reduce P. aeruginosa-related illness and mortality using immunoinformatics resources. The ultimate complex has been determined to be stable, soluble, antigenic, and non-allergenic upon inspection of its physicochemical and immunological properties. Additionally, the protein exhibited acidic and hydrophilic characteristics. The Ramachandran plot, ProSA-web, ERRAT, and Verify3D were employed to ensure the final model's authenticity once the protein's three-dimensional structure had been established and refined. The vaccine model showed a significant binding score and stability when interacting with MHC receptors. Population coverage analysis indicated a global coverage rate of 83.40%, with the USA having the highest coverage rate, exceeding 90%. Moreover, the vaccine sequence underwent codon optimization before being cloned into the Escherichia coli plasmid vector pET-28a (+) at the EcoRI and EcoRV restriction sites. Our research has developed a vaccine against P. aeruginosa that has strong binding affinity and worldwide coverage, offering an acceptable way to mitigate nosocomial infections.
Sujet(s)
Biologie informatique , Infections à Pseudomonas , Pseudomonas aeruginosa , Sepsie , Pseudomonas aeruginosa/immunologie , Pseudomonas aeruginosa/génétique , Humains , Infections à Pseudomonas/prévention et contrôle , Infections à Pseudomonas/immunologie , Infections à Pseudomonas/microbiologie , Sepsie/prévention et contrôle , Sepsie/immunologie , Sepsie/microbiologie , Biologie informatique/méthodes , Épitopes/immunologie , Épitopes/composition chimique , Pneumopathie infectieuse/prévention et contrôle , Pneumopathie infectieuse/immunologie , Pneumopathie infectieuse/microbiologie , Vaccins antipseudomonas/immunologie , Vaccins antibactériens/immunologie , Protéines bactériennes/immunologie , Protéines bactériennes/génétiqueRÉSUMÉ
Lyme disease is caused by the spirochete, Borrelia burgdorferi, which is transmitted by Ixodes spp ticks. The rise in Lyme disease cases since its discovery in the 1970s has reinforced the need for a vaccine. A vaccine based on B burgdorferi outer surface protein A (OspA) was approved by the Food and Drug Administration (FDA) several decades ago, but was pulled from the market a few years later, reportedly due to poor sales, despite multiple organizations concluding that it was safe and effective. Newer OspA-based vaccines are being developed and are likely to be available in the coming years. More recently, there has been a push to develop vaccines that target the tick vector instead of the pathogen to inhibit tick feeding and thus prevent transmission of tick-borne pathogens to humans and wildlife reservoirs. This review outlines the history of Lyme disease vaccines and this movement to anti-tick vaccine approaches.
Sujet(s)
Borrelia burgdorferi , Ixodes , Vaccins contre la maladie de Lyme , Maladie de Lyme , Maladie de Lyme/prévention et contrôle , Maladie de Lyme/immunologie , Humains , Animaux , Borrelia burgdorferi/immunologie , Vaccins contre la maladie de Lyme/immunologie , Ixodes/microbiologie , Vaccination , Protéines de la membrane externe bactérienne/immunologie , Vaccins antibactériens/immunologie , Vaccins antibactériens/administration et posologie , Antigènes de surface/immunologie , Lipoprotéines/immunologieSujet(s)
Vaccins antibactériens , Peau , Syphilis , Treponema pallidum , Humains , Treponema pallidum/immunologie , Syphilis/immunologie , Peau/microbiologie , Peau/immunologie , Vaccins antibactériens/immunologie , Protéines bactériennes/immunologie , Lymphocytes T/immunologie , Développement de vaccinRÉSUMÉ
Extracellular vesicles are nanosized lipid-bilayered spheres secreted from every living cell and they serve physiological and pathophysiological functions. Bacterial membrane vesicles are shed from both Gram-negative and Gram-positive bacteria and harbor many virulence factors, nuclear material, polysaccharides, proteins, and antigenic determinants, which are essential for immune recognition and evasion. Hence, bacterial membrane vesicles are very promising vaccine candidates. Spray drying is a well-established pharmaceutical technique to produce inhalable dry powders with enhanced stability for formulations of vaccines. In this chapter, we illustrate general guidelines for spray drying of bacterial extracellular vesicles to improve their stability without compromising their immunogenic protective effect. We discuss some of the most important experiments to characterize the generated spray-dried bacterial membrane vesicle powder vaccine.
Sujet(s)
Vésicules extracellulaires , Vésicules extracellulaires/composition chimique , Vésicules extracellulaires/métabolisme , Vésicules extracellulaires/immunologie , Vaccins antibactériens/immunologie , Vaccins antibactériens/composition chimique , Séchage par pulvérisation , Poudres/composition chimique , Humains , Membrane cellulaire/métabolisme , Membrane cellulaire/composition chimique , AnimauxRÉSUMÉ
Engineered outer membrane vesicles (OMVs) derived from Gram-negative bacteria are a promising vaccine technology for developing immunity against diverse pathogens. However, antigen display on OMVs can be challenging to control and highly variable due to bottlenecks in protein expression and localization to the bacterial host cell's outer membrane, especially for bulky and complex antigens. Here, we describe methods related to a universal vaccine technology called AvidVax (avidin-based vaccine antigen crosslinking) for rapid and simplified assembly of antigens on the exterior of OMVs during vaccine development. The AvidVax platform involves remodeling the OMV surface with multiple copies of a synthetic antigen-binding protein (SNAP), which is an engineered fusion protein comprised of an outer membrane scaffold protein linked to a biotin-binding protein. The resulting SNAPs enable efficient decoration of OMVs with a molecularly diverse array of biotinylated subunit antigens, including globular and membrane proteins, glycans and glycoconjugates, haptens, lipids, nucleic acids, and short peptides. We detail the key steps in the AvidVax vaccine production pipeline including preparation and isolation of SNAP-OMVs, biotinylation and enrichment of vaccine antigens, and formulation and characterization of antigen-loaded SNAP-OMVs.
Sujet(s)
Antigènes bactériens , Biotinylation , Vésicules extracellulaires , Vésicules extracellulaires/immunologie , Vésicules extracellulaires/métabolisme , Antigènes bactériens/immunologie , Antigènes bactériens/génétique , Vaccins antibactériens/immunologie , Protéines de la membrane externe bactérienne/immunologie , Protéines de la membrane externe bactérienne/métabolisme , Protéines de la membrane externe bactérienne/génétique , Développement de vaccin , Membrane bactérienne externe/métabolisme , Membrane bactérienne externe/immunologieRÉSUMÉ
BACKGROUND: Enterococcus faecium and Staphylococcus aureus are the Gram-positive pathogens of the ESKAPE group, known to represent a great threat to human health due to their high virulence and multiple resistances to antibiotics. Combined, enterococci and S. aureus account for 26% of healthcare-associated infections and are the most common organisms responsible for blood stream infections. We previously showed that the peptidyl-prolyl cis/trans isomerase (PPIase) PpiC of E. faecium elicits the production of specific, opsonic, and protective antibodies that are effective against several strains of E. faecium and E. faecalis. Due to the ubiquitous characteristics of PPIases and their essential function within Gram-positive cells, we hypothesized a potential cross-reactive effect of anti-PpiC antibodies. RESULTS: Opsonophagocytic assays combined with bioinformatics led to the identification of the foldase protein PrsA as a new potential vaccine antigen in S. aureus. We show that PrsA is a stable dimeric protein able to elicit opsonic antibodies against the S. aureus strain MW2, as well as cross-binding and cross-opsonic in several S. aureus, E. faecium and E. faecalis strains. CONCLUSIONS: Given the multiple antibiotic resistances S. aureus and enterococci present, finding preventive strategies is essential to fight those two nosocomial pathogens. The study shows the potential of PrsA as an antigen to use in vaccine formulation against the two dangerous Gram-positive ESKAPE bacteria. Our findings support the idea that PPIases should be further investigated as vaccine targets in the frame of pan-vaccinomics strategy.
Sujet(s)
Protéines bactériennes , Enterococcus faecalis , Enterococcus faecium , Peptidylpropyl isomerase , Staphylococcus aureus , Staphylococcus aureus/immunologie , Staphylococcus aureus/génétique , Enterococcus faecium/immunologie , Enterococcus faecium/génétique , Protéines bactériennes/immunologie , Protéines bactériennes/génétique , Peptidylpropyl isomerase/immunologie , Peptidylpropyl isomerase/génétique , Enterococcus faecalis/immunologie , Enterococcus faecalis/génétique , Humains , Infections bactériennes à Gram positif/prévention et contrôle , Infections bactériennes à Gram positif/immunologie , Infections bactériennes à Gram positif/microbiologie , Vaccins antibactériens/immunologie , Opsonines/immunologie , Anticorps antibactériens/immunologie , Anticorps antibactériens/sang , Animaux , Réactions croisées , Souris , Antigènes bactériens/immunologie , Antigènes bactériens/génétique , Phagocytose , Infections à staphylocoques/prévention et contrôle , Infections à staphylocoques/immunologie , Infections à staphylocoques/microbiologieRÉSUMÉ
OBJECTIVES: The pathogenic microorganisms that cause intestinal diseases can significantly jeopardize people's health. Currently, there are no authorized treatments or vaccinations available to combat the germs responsible for intestinal disease. METHODS: Using immunoinformatics, we developed a potent multi-epitope Combination (combo) vaccine versus Salmonella and enterohemorrhagic E. coli. The B and T cell epitopes were identified by performing a conservancy assessment, population coverage analysis, physicochemical attributes assessment, and secondary and tertiary structure assessment of the chosen antigenic polypeptide. The selection process for vaccine development included using several bioinformatics tools and approaches to finally choose two linear B-cell epitopes, five CTL epitopes, and two HTL epitopes. RESULTS: The vaccine had strong immunogenicity, cytokine production, immunological properties, non-toxicity, non-allergenicity, stability, and potential efficacy against infections. Disulfide bonding, codon modification, and computational cloning were also used to enhance the stability and efficacy of expression in the host E. coli. The vaccine's structure has a strong affinity for the TLR4 ligand and is very durable, as shown by molecular docking and molecular modeling. The results of the immunological simulation demonstrated that both B and T cells had a heightened response to the vaccination component. CONCLUSIONS: The comprehensive in silico analysis reveals that the proposed vaccine will likely elicit a robust immune response against pathogenic bacteria that cause intestinal diseases. Therefore, it is a promising option for further experimental testing.
Sujet(s)
Déterminants antigéniques des lymphocytes B , Déterminants antigéniques des lymphocytes T , Vaccinologie , Humains , Déterminants antigéniques des lymphocytes T/immunologie , Vaccinologie/méthodes , Déterminants antigéniques des lymphocytes B/immunologie , Vaccins combinés/immunologie , Génomique/méthodes , Escherichia coli entérohémorrhagique/immunologie , Salmonella/immunologie , Animaux , Biologie informatique/méthodes , Simulation de docking moléculaire , Vaccins anti-Escherichia coli/immunologie , Infections à Escherichia coli/prévention et contrôle , Infections à Escherichia coli/immunologie , Salmonelloses/immunologie , Salmonelloses/prévention et contrôle , Antigènes bactériens/immunologie , Développement de vaccin/méthodes , Vaccins antibactériens/immunologieRÉSUMÉ
Leptospirosis, a neglected zoonotic disease, is caused by pathogenic spirochetes belonging to the genus Leptospira and has one of the highest morbidity and mortality rates worldwide. Vaccination stands out as one of the most effective preventive measures for susceptible populations. Within the outer membrane of Leptospira spp., we find the LIC12287, LIC11711, and LIC13259 lipoproteins. These are of interest due to their surface location and potential immunogenicity. Thorough examination revealed the conservation of these proteins among pathogenic Leptospira spp.; we mapped the distribution of T- and B-cell epitopes along their sequences and assessed the 3D structures of each protein. This information aided in selecting immunodominant regions for the development of a chimeric protein. Through gene synthesis, we successfully constructed a chimeric protein, which was subsequently expressed, purified, and characterized. Hamsters were immunized with the chimeric lipoprotein, formulated with adjuvants aluminum hydroxide, EMULSIGEN®-D, Sigma Adjuvant System®, and Montanide™ ISA206VG. Another group was vaccinated with an inactivated Escherichia coli bacterin expressing the chimeric protein. Following vaccination, hamsters were challenged with a virulent L. interrogans strain. Our evaluation of the humoral immune response revealed the production of IgG antibodies, detectable 28 days after the second dose, in contrast to pre-immune samples and control groups. This demonstrates the potential of the chimeric protein to elicit a robust humoral immune response; however, no protection against challenge was achieved. While this study provides valuable insights into the subject, further research is warranted to identify protective antigens that could be utilized in the development of a leptospirosis vaccine. KEY POINTS: ⢠Several T- and B-cell epitopes were identified in all the three proteins. ⢠Four different adjuvants were used in vaccine formulations. ⢠Immunization stimulated significant levels of IgG2/3 in vaccinated animals.
Sujet(s)
Anticorps antibactériens , Vaccins antibactériens , Leptospirose , Lipoprotéines , Animaux , Leptospirose/prévention et contrôle , Leptospirose/immunologie , Lipoprotéines/immunologie , Lipoprotéines/génétique , Vaccins antibactériens/immunologie , Vaccins antibactériens/génétique , Anticorps antibactériens/sang , Anticorps antibactériens/immunologie , Cricetinae , Déterminants antigéniques des lymphocytes B/immunologie , Déterminants antigéniques des lymphocytes B/génétique , Protéines de fusion recombinantes/immunologie , Protéines de fusion recombinantes/génétique , Adjuvants immunologiques/administration et posologie , Immunoglobuline G/sang , Déterminants antigéniques des lymphocytes T/immunologie , Déterminants antigéniques des lymphocytes T/génétique , Leptospira interrogans/immunologie , Leptospira interrogans/génétique , Protéines de la membrane externe bactérienne/immunologie , Protéines de la membrane externe bactérienne/génétique , Vaccination , Immunité humorale , Leptospira/immunologie , Leptospira/génétique , Immunogénicité des vaccinsRÉSUMÉ
A simple IgG-speciï¬c ELISA for Leptospira spp. was compared with the microscopic agglutination test (MAT) to detect IgG antibody responses to a commercial vaccine in cattle. We used an enzyme-linked immunosorbent assay (ELISA) with sonicated Leptospira interrogans serovar copenhageni M 20. After initial vaccination, specific antibodies against Leptospira spp. were detected in 90â¯% of the animals by IgG-ELISA and 60â¯% by MAT, while after booster, antibodies were detected in 100â¯% and 80â¯% of the animals by IgG-ELISA and MAT, respectively. Both serological MAT and ELISA tests revealed interferences of vaccine antibodies. Disease diagnosis with ELISA and MAT methods should be made two and a half months and four months, respectively, after vaccination to avoid interference of vaccine antibodies. On the other hand, our results suggest that IgG-ELISA may be a useful method to assess the development of IgG antibodies induced by Leptospira vaccine.
Sujet(s)
Tests d'agglutination , Anticorps antibactériens , Vaccins antibactériens , Maladies des bovins , Test ELISA , Immunoglobuline G , Leptospirose , Animaux , Leptospirose/médecine vétérinaire , Leptospirose/diagnostic , Leptospirose/immunologie , Bovins , Maladies des bovins/microbiologie , Maladies des bovins/diagnostic , Maladies des bovins/immunologie , Maladies des bovins/sang , Test ELISA/médecine vétérinaire , Anticorps antibactériens/sang , Vaccins antibactériens/immunologie , Immunoglobuline G/sang , Tests d'agglutination/médecine vétérinaire , Leptospira interrogans/immunologie , Leptospira/immunologie , Vaccination/médecine vétérinaire , Tests sérologiques/médecine vétérinaireRÉSUMÉ
Egg yolk antibodies (IgY) can be prepared in large quantities and economically, and have potential value as polyvalent passive vaccines (against multiple bacteria) in aquaculture. This study prepared live and inactivated Vibrio fluvialis IgY and immunized Carassius auratus prior to infection with V. fluvialis and Aeromonas hydrophila. The results showed that the two IgY antibodies hold effective passive protective rates against V. fluvialis and A. hydrophila in C. auratus. Further, the serum of C. auratus recognized the two bacteria in vitro, with a decrease in the bacteria content of the kidney. The phagocytic activity of C. auratus plasma was enhanced, with a decrease in the expression of inflammatory and antioxidant factors. Pathological sections showed that the kidney, spleen, and intestinal tissue structures were intact, and apoptosis and DNA damage decreased in kidney cells. Moreover, the immunoprotection conferred by the live V. fluvialis IgY was higher than that of the inactivated IgY. Addition, live V. fluvialis immunity induced IgY antibodies against outer membrane proteins of V. fluvialis were more than inactivated V. fluvialis immunity. Furthermore, heterologous immune bacteria will not cause infection, so V. fluvialis can be used to immunize chickens to obtain a large amount of IgY antibody. These findings suggest that the passive immunization effect of live bacterial IgY antibody on fish is significantly better than that of inactivated bacterial antibody, and the live V. fluvialis IgY hold potential value as polyvalent passive vaccines in aquaculture.
Sujet(s)
Aeromonas hydrophila , Jaune d'Åuf , Maladies des poissons , Immunoglobulines , Infections à Vibrio , Vibrio , Animaux , Immunoglobulines/immunologie , Immunoglobulines/sang , Infections à Vibrio/médecine vétérinaire , Infections à Vibrio/immunologie , Infections à Vibrio/prévention et contrôle , Vibrio/immunologie , Maladies des poissons/immunologie , Maladies des poissons/prévention et contrôle , Jaune d'Åuf/immunologie , Aeromonas hydrophila/immunologie , Poisson rouge/immunologie , Infections bactériennes à Gram négatif/immunologie , Infections bactériennes à Gram négatif/médecine vétérinaire , Infections bactériennes à Gram négatif/prévention et contrôle , Anticorps antibactériens/sang , Anticorps antibactériens/immunologie , Immunisation passive/médecine vétérinaire , Vaccins antibactériens/immunologie , Vaccins antibactériens/administration et posologieRÉSUMÉ
BACKGROUND: Venereal syphilis, caused by the spirochete Treponema pallidum subsp. pallidum (TPA), is surging worldwide, underscoring the need for a vaccine with global efficacy. Vaccine development requires an understanding of syphilis epidemiology and clinical presentation as well as genomic characterization of TPA strains circulating within at-risk populations. The aim of this study was to describe the clinical, demographic, and molecular features of early syphilis cases in Cali, Colombia. METHODS AND FINDINGS: We conducted a cross-sectional study to identify individuals with early syphilis (ES) in Cali, Colombia through a city-wide network of public health centers, private sector HIV clinics and laboratory databases from public health institutions. Whole blood (WB), skin biopsies (SB), and genital and oral lesion swabs were obtained for measurement of treponemal burdens by polA quantitative polymerase chain reaction (qPCR) and for whole-genome sequencing (WGS). Among 1,966 individuals screened, 128 participants met enrollment criteria: 112 (87%) with secondary (SS), 15 (12%) with primary (PS) and one with early latent syphilis; 66/128 (52%) self-reported as heterosexual, while 48 (38%) were men who have sex with men (MSM). Genital ulcer swabs had the highest polA copy numbers (67 copies/µl) by qPCR with a positivity rate (PR) of 73%, while SS lesions had 42 polA copies/µl with PR of 62%. WB polA positivity was more frequent in SS than PS (42% vs 7%, respectively; p = 0.009). Isolation of TPA from WB by rabbit infectivity testing (RIT) was achieved in 5 (56%) of 9 ES WB samples tested. WGS from 33 Cali patient samples, along with 10 other genomic sequences from South America (9 from Peru, 1 from Argentina) used as comparators, confirmed that SS14 was the predominant clade, and that half of all samples had mutations associated with macrolide (i.e., azithromycin) resistance. Variability in the outer membrane protein (OMP) and vaccine candidate BamA (TP0326) was mapped onto the protein's predicted structure from AlphaFold. Despite the presence of mutations in several extracellular loops (ECLs), ECL4, an immunodominant loop and proven opsonic target, was highly conserved in this group of Colombian and South American TPA isolates. CONCLUSIONS: This study offers new insights into the sociodemographic and clinical features of venereal syphilis in a highly endemic area of Colombia and illustrates how genomic sequencing of regionally prevalent TPA strains can inform vaccine development.
Sujet(s)
Syphilis , Treponema pallidum , Humains , Treponema pallidum/génétique , Treponema pallidum/immunologie , Treponema pallidum/isolement et purification , Colombie/épidémiologie , Syphilis/épidémiologie , Syphilis/microbiologie , Études transversales , Mâle , Adulte , Femelle , Vaccins antibactériens/immunologie , Variation génétique , Développement de vaccin , Jeune adulte , Adulte d'âge moyen , Séquençage du génome entier , AnimauxRÉSUMÉ
Rhodococcus equi (R. equi) is a zoonotic opportunistic pathogen that mainly causes fatal lung and extrapulmonary abscesses in foals and immunocompromised individuals. To date, no commercial vaccine against R. equi exists. We previously screened all potential vaccine candidates from the complete genome of R. equi using a reverse vaccinology approach. Five of these candidates, namely ABC transporter substrate-binding protein (ABC transporter), penicillin-binding protein 2 (PBD2), NlpC/P60 family protein (NlpC/P60), esterase family protein (Esterase), and M23 family metallopeptidase (M23) were selected for the evaluation of immunogenicity and immunoprotective effects in BALB/c mice model challenged with R. equi. The results showed that all five vaccine candidate-immunized mice experienced a significant increase in spleen antigen-specific IFN-γ- and TNF-α-positive CD4 + and CD8 + T lymphocytes and generated robust Th1- and Th2-type immune responses and antibody responses. Two weeks after the R. equi challenge, immunization with the five vaccine candidates reduced the bacterial load in the lungs and improved the pathological damage to the lungs and livers compared with those in the control group. NlpC/P60, Esterase, and M23 were more effective than the ABC transporter and PBD2 in inducing protective immunity against R. equi challenge in mice. In addition, these vaccine candidates have the potential to induce T lymphocyte memory immune responses in mice. In summary, these antigens are effective candidates for the development of protective vaccines against R. equi. The R. equi antigen library has been expanded and provides new ideas for the development of multivalent vaccines.
Sujet(s)
Infections à Actinomycetales , Vaccins antibactériens , Modèles animaux de maladie humaine , Immunité humorale , Souris de lignée BALB C , Rhodococcus equi , Animaux , Rhodococcus equi/immunologie , Rhodococcus equi/génétique , Souris , Vaccins antibactériens/immunologie , Vaccins antibactériens/administration et posologie , Infections à Actinomycetales/prévention et contrôle , Infections à Actinomycetales/immunologie , Infections à Actinomycetales/microbiologie , Anticorps antibactériens/sang , Anticorps antibactériens/immunologie , Immunité cellulaire , Femelle , Poumon/microbiologie , Poumon/immunologie , Poumon/anatomopathologie , Charge bactérienne , Protéines bactériennes/immunologie , Protéines bactériennes/génétique , Interféron gamma/immunologie , Interféron gamma/métabolismeRÉSUMÉ
Staphylococcus aureus, Escherichia coli and Mycoplasma bovis are the most commonly isolated mastitis pathogens. The aim of this study was to evaluate the efficacy of a new mixed vaccine against mastitis caused by Staphylococcus aureus, Escherichia coli, and Mycoplasma bovis. For this purpose, a mixed inactivated vaccine was administered subcutaneously to 24 heifers as one dose (2 mL) on the 45th day before birth and the second dose 21 days later. In 9 heifers, 2 mL of PBS was administered as placebo instead of vaccine. Then, heifers were divided into 3 groups as 7 vaccinated and 3 unvaccinated animals. Staphylococcus aureus, Escherichia coli, and Mycoplasma bovis were administered to the groups through intramammary route. Three vaccinated heifers were considered the common control without bacteria in all groups. The parameters considered to assess the effect of vaccination were clinical findings, bacterial count in milk, somatic cell count, and antibody titers. Clinical signs were observed only in the unvaccinated placebo group. Bacteria count and somatic cell count in milk increased in vaccinated and unvaccinated heifers. However, this increase was less in vaccinated animals and gradually returned to the normal level. In the unvaccinated heifers, it was ever high. Serum antibody titers were measured before and after vaccination. Antibody titers were high in vaccinated heifers after vaccination and were negative in unvaccinated heifers. In conclusion, the mixed vaccine had beneficial effect against Staphylococcus aureus, Escherichia coli, and Mycoplasma bovis mastitis and stimulated the immune response of vaccinated heifers.
Sujet(s)
Escherichia coli , Mammite bovine , Infections à Mycoplasma , Mycoplasma bovis , Infections à staphylocoques , Staphylococcus aureus , Vaccins inactivés , Animaux , Bovins , Mycoplasma bovis/immunologie , Femelle , Mammite bovine/prévention et contrôle , Mammite bovine/microbiologie , Mammite bovine/immunologie , Staphylococcus aureus/immunologie , Infections à Mycoplasma/médecine vétérinaire , Infections à Mycoplasma/prévention et contrôle , Vaccins inactivés/immunologie , Infections à staphylocoques/prévention et contrôle , Infections à staphylocoques/médecine vétérinaire , Vaccins antibactériens/immunologie , Vaccins antibactériens/administration et posologie , Infections à Escherichia coli/prévention et contrôle , Infections à Escherichia coli/médecine vétérinaire , Infections à Escherichia coli/immunologieRÉSUMÉ
Infectious coryza (IC) is an acute upper respiratory disease of chicken caused by Avibacterium (A.) paragallinarum. This disease results in an increased culling rate in meat chicken and a marked decrease in egg production (10% to more than 40%) in laying and breeding hens. Vaccines were first used against IC and effectively controlled the disease. Nanotechnology provides an excellent way to develop a new generation of vaccines. NPs have been widely used in vaccine design as adjuvants and antigen delivery vehicles and as antibacterial agents; thus, they can be used as inactivators for bacterial culture. In this research, the antibacterial effects of several nanoparticles (NPs), such as silicon dioxide with chitosan (SiO2-CS), oleoyl-chitosan (O.CS), silicon dioxide (SiO2), and iron oxide (Fe3O4), on A. paragallinarum were studied. Additionally, different A. paragallinarum vaccines were made using the same nanomaterials at a concentration of 400 µg/ml to help control infectious coryza disease in chicken. A concentration of 400 µg/ml of all the NPs tested was the best concentration for the inactivation of A. paragallinarum. Additionally, this study showed that the infectious coryza vaccine adjuvanted with SiO2 NPs had the highest immune response, followed by the infectious coryza vaccine adjuvanted with Fe3O4 NPs, the infectious coryza vaccine adjuvanted with SiO2-CS NPs, and the infectious coryza vaccine adjuvanted with O.CS NPs in comparison with the infectious coryza vaccine adjuvanted with liquid paraffin (a commercial vaccine).
Sujet(s)
Adjuvants immunologiques , Poulets , Chitosane , Nanoparticules , Maladies de la volaille , Animaux , Poulets/immunologie , Maladies de la volaille/prévention et contrôle , Maladies de la volaille/immunologie , Nanoparticules/composition chimique , Chitosane/composition chimique , Adjuvants immunologiques/pharmacologie , Vaccins antibactériens/immunologie , Vaccins antibactériens/administration et posologie , Silice/composition chimique , Adjuvants vaccinaux , Polymères/composition chimique , Vecteurs de médicaments/composition chimique , Pasteurellaceae/immunologieRÉSUMÉ
Fowl cholera is an infectious disease that affects both poultry and wild birds, characterized by hemorrhagic and septicemic symptoms, caused by Pasteurella multocida (P. multocida), and leading to substantial economic losses in the poultry sector. The development of genetic engineering vaccines against avian P. multocida encountered early-stage challenges due to the limited availability of effective gene editing tools. Presently, NgAgoDM-enhanced homologous recombination stands as a potent technique for achieving efficient gene knockout in avian P. multocida. Hence, this study employed NgAgoDM-enhanced homologous recombination to target and knockout hyaE (239-359aa), hyaD, hexABC, and hexD, denoted as ΔhyaE (239-359aa), ΔhyaD, ΔhexABC, and ΔhexD, respectively. Additionally, we generated a hyaD recovery strain with two point mutations, designated as mhyaD. Thus, this study systematically examined the impact of capsular synthetic gene clusters on the pathogenicity of P. multocida. Moreover, the study demonstrated the critical role of hyaD activity in the virulence of avian P. multocida. This study offers novel insights for enhancing attenuated vaccines further.
Sujet(s)
Pasteurelloses , Pasteurella multocida , Maladies de la volaille , Pasteurella multocida/génétique , Pasteurella multocida/pathogénicité , Animaux , Pasteurelloses/médecine vétérinaire , Pasteurelloses/microbiologie , Virulence/génétique , Maladies de la volaille/microbiologie , Vaccins antibactériens/immunologie , Vaccins antibactériens/génétique , Recombinaison homologue , Vaccins atténués/immunologie , Vaccins atténués/génétique , Techniques de knock-out de gènes , Poulets/microbiologie , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Oiseaux/microbiologie , Famille multigénique , Facteurs de virulence/génétique , Volaille/microbiologieRÉSUMÉ
Vaccination is the most effective method for preventing infectious diseases. Oral vaccinations have attracted much attention due to the ability to boost intestinal and systemic immunity. The focus of this study was to develop a poly (lactide-co-glycolide) acid (PLGA)-based ternary polyelectrolyte complex (PEC) with chitosan, sodium alginate, and transmembrane peptides R8 for the delivery of antigen proteins. In this study, the antigen protein (HBf), consisting of the Mycobacterium avium subspecies paratuberculosis (MAP) antigens HBHA, Ag85B, and Bfra, was combined with R8 to generate self-assembled conjugates. The results showed that PEC presented a cross-linked reticular structure to protect the encapsulated proteins in the simulated gastric fluid. Then, the nanocomposite separated into individual nanoparticles after entering the simulated intestinal fluid. The ternary PEC with R8 promoted the in vivo uptake of antigens by intestinal lymphoid tissue. Moreover, the ternary PEC administered orally to mice promoted the secretion of specific antibodies and intestinal mucosal IgA. In addition, in the mouse models of MAP infection, the ternary PEC enhanced splenic T cell responses, thus reducing bacterial load and liver pathology score. These results suggested that this ternary electrolyte complex could be a promising delivery platform for oral subunit vaccine candidates, not limited to MAP infection.
Sujet(s)
Alginates , Chitosane , Immunité muqueuse , Chitosane/composition chimique , Alginates/composition chimique , Animaux , Immunité muqueuse/effets des médicaments et des substances chimiques , Souris , Administration par voie orale , Polyélectrolytes/composition chimique , Femelle , Souris de lignée BALB C , Antigènes bactériens/immunologie , Antigènes bactériens/composition chimique , Vaccins antibactériens/immunologie , Vaccins antibactériens/administration et posologie , Vaccins antibactériens/composition chimiqueRÉSUMÉ
AIMS: Currently, immunoinformatic approaches have shown promise in rapidly and cost-effectively identifying new antigens from the Leptospira proteome. Chimeric multiepitope proteins offer a strategy with significant potential for implementation in diagnosis and vaccines development. METHODS AND RESULTS: In this study, we detail the immunoinformatic analyses and design of a new recombinant chimeric protein constructed with epitopes identified from the sequences of ErpY-like and LemA proteins, previously identified as potential antigens for controlling leptospirosis. We expressed the chimeric protein using Escherichia coli heterologous systems, evaluated its antigenicity using serum from naturally infected patients, and its immunogenicity in mice as an animal model, with Freund as an adjuvant. The resulting recombinant chimeric protein, named rErpY-LemA, was successfully expressed and purified using a prokaryotic system, with an expected mass of 35 kDa. Serologic assays using serum samples from naturally infected patients demonstrated recognition of the chimera protein by antibodies present in sera. Animals immunized with the chimera exhibited a significant IgG antibody response from the 7th day (P < 0.001), persisting until day 49 of experimentation, with a titer of 1:12,800 (P < 0.05). Notably, significant production of IgA, IgM, and IgG subclasses was observed in animals immunized with the chimera. CONCLUSIONS: These results highlight the promising role of immunoinformatics in rapidly identifying antigens and the potential of chimeric multiepitope proteins in developing effective strategies for leptospirosis control.